At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
Pharmacokineticdrug
Likely dose
Pharmacokinetic 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nicotinic Receptors and Schizophrenia
In Brief
A Phase 1 clinical trial evaluating Pharmacokinetic for Schizophrenia. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartJan 2010
Primary CompletionOct 2014
TodayJul 2026
First PostedAug 6, 2009
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.9 years ago
Interventions
Pharmacokineticdrug
Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined